Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma

Clinica Chimica Acta

Volumn 412, Issue 7-8, 2011, Pages 562-568

  Uljon, Sacha N ^a,c   Richardson, Paul G ^b,c   Schur, Peter H ^a,c   Anderson, Kenneth C ^b,c   Tanasijevic, Milenko J ^a,c   Lindeman, Neal I ^a,c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Myeloma; Serum free light chains; Serum protein electrophoresis

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN GA; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE; UNCLASSIFIED DRUG;

ARTICLE; CANCER RELAPSE; CANCER RESISTANCE; CLINICAL ARTICLE; CROSS REACTION; ELECTROPHORESIS; FOLLOW UP; HEALTH STATUS; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; INTACT IMMUNOGLOBULIN MYELOMA; MULTIPLE MYELOMA; PRIORITY JOURNAL; SPIKE;

HUMANS; MULTIPLE MYELOMA; MYELOMA PROTEINS;

EID: 79551470406     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.12.002     Document Type: Article

References (17)

1. Bradwell A.R., Carr-Smith H.D., Mead G.P., et al. Highly sensitive, automated immunoassay for immunoglobulin free light chains in serum and urine. Clin Chem 2001, 47(4):673-680.
2. Dispenzieri A., Kyle R., Merlini G., et al. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 2009, 23(2):215-224.
3. Drayson M., Tang L.X., Drew R., Mead G.P., Carr-Smith H., Bradwell A.R. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood 2001, 97(9):2900-2902.
4. Kumar S.K., Rajkumar S.V., Dispenzieri A., et al. Improved survival in multiple myeloma and the impact of novel therapies. Blood 2008, 111(5):2516-2520.
5. Katzmann J.A., Clark R.J., Abraham R.S., et al. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains. Clin Chem 2002, 48(9):1437-1444.
6. Das M., Mead G.P., Sreekankth V., Anderson J., et al. Concentration kinetics in patients receiving bortezomib: temporary inhibition of protein synthesis and early biomarker for disease response. Blood 2005, 106(11):5094.
7. Nakano T., Miyazaki S., Takahashi H., et al. Immunochemical quantification of free immunoglobulin light chains from an analytical perspective. Clin Chem Lab Med 2006, 44(5):522-532.
8. Bradwell A.R. Serum Free Light Chain Analysis 2004, The Binding Site, Birmingham, UK. 2nd ed.
9. Simpson E.R., Herold E.M., Buchner J. The folding pathway of the antibody V(L) domain. J Mol Biol 2009, 392(5):1326-1338.
10. Blancas-Mejia L.M., Tellez L.A., del Pozo-Yauner L., Becerril B., Sanchez-Ruiz J.M., Fernandez-Velasco D.A. Thermodynamic and kinetic characterization of a germ line human lambda6 light-chain protein: the relation between unfolding and fibrillogenesis. J Mol Biol 2009, 386(4):1153-1166.
11. Sikkink L.A., Ramirez-Alvarado M. Biochemical and aggregation analysis of Bence Jones proteins from different light chain diseases. Amyloid 2008, 15(1):29-39.
12. Tate J., Bazeley S., Sykes S., Mollee P. Quantitative serum free light chain assay-analytical issues. Clin. Biochem. Rev. 2009, 30(3):131-140.
13. Miettinen T.A., Kekki M. Effect of impaired hepatic and renal function on Bence Jones protein catabolism in human subjects. Clin Chim Acta 1967, 18:395-407.
14. Wochner R.D., Strober W., Waldmann T.A. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J Exp Med 1967, 126(2):207-221.
15. Kaplan B., Ramirez-Alvarado M., Sikkink L., et al. Free light chains in plasma of patients with light chain amyloidosis and non-amyloid light chain deposition disease. High proportion and heterogeneity of disulfide-linked monoclonal free light chains as pathogenic features of amyloid disease. Br J Haematol 2009, 144(5):705-715.
16. Mead G.P., Carr-Smith H.D., Drayson M.T., Morgan G.J., Child J.A., Bradwell A.R. Serum free light chains for monitoring multiple myeloma. Br J Haematol 2004, 126(3):348-354.
17. Kuhnemund A., Liebisch P., Bauchmuller K., zur Hausen A., Veelken H., Wasch R., et al. 'Light-chain escape-multiple myeloma' - an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol 2009, 135(3):477-484.